Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide by López-Valero, Israel et al.
Contents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.elsevier.com/locate/biochempharm
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids
and temozolomide
Israel López-Valeroa,b,c, Cristina Saiz-Laderaa,b,c, Sofía Torresa, Sonia Hernández-Tiedraa,b,
Elena García-Taboadaa,d, Fátima Rodríguez-Fornésa, Marina Barbaa, David Dávilaa,b,
Nélida Salvador-Tormoa,b, Manuel Guzmána,c,d, Juan M. Sepúlvedae, Pilar Sánchez-Gómezf,
Mar Lorentea,b,c,1, Guillermo Velascoa,b,c,⁎,1
a Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain
b Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040 Madrid, Spain
c Instituto Universitario de Investigación Neuroquímica, Complutense University, 28040 Madrid, Spain
d Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Spain
eNeuro-oncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
fNeuro-oncology Unit, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain








A B S T R A C T
Glioblastoma multiforme (GBM) is the most frequent and aggressive type of brain tumor due, at least in part, to
its poor response to current anticancer treatments. These features could be explained, at least partially, by the
presence within the tumor mass of a small population of cells termed Glioma Initiating Cells (GICs) that has been
proposed to be responsible for the relapses occurring in this disease. Thus, the development of novel therapeutic
approaches (and specifically those targeting the population of GICs) is urgently needed to improve the survival
of the patients suffering this devastating disease. Previous observations by our group and others have shown that
Δ9-Tetrahydrocannabinol (THC, the main active ingredient of marijuana) and other cannabinoids including
cannabidiol (CBD) exert antitumoral actions in several animal models of cancer, including gliomas. We also
found that the administration of THC (or of THC+CBD at a 1:1 ratio) in combination with temozolomide
(TMZ), the benchmark agent for the treatment of GBM, synergistically reduces the growth of glioma xenografts.
In this work we investigated the effect of the combination of TMZ and THC:CBD mixtures containing different
ratios of the two cannabinoids in preclinical glioma models, including those derived from GICs. Our findings
show that TMZ+THC:CBD combinations containing a higher proportion of CDB (but not TMZ+CBD alone)
produce a similar antitumoral effect as the administration of TMZ together with THC and CBD at a 1:1 ratio in
xenografts generated with glioma cell lines. In addition, we also found that the administration of
TMZ+THC:CBD at a 1:1 ratio reduced the growth of orthotopic xenografts generated with GICs derived from
GBM patients and enhanced the survival of the animals bearing these intracranial xenografts. Remarkably, the
antitumoral effect observed in GICs-derived xenografts was stronger when TMZ was administered together with
cannabinoid combinations containing a higher proportion of CBD. These findings support the notion that the
administration of TMZ together with THC:CBD combinations – and specifically those containing a higher pro-
portion of CBD – may be therapeutically explored to target the population of GICs in GBM.
1. Introduction
Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the
most frequent class of malignant primary brain tumor and one of the
most aggressive forms of cancer. Consequently, median survival upon
diagnosis is just 12–15months [1–3]. This dramatic behavior has been
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attributed to the high invasiveness and proliferation rate exhibited by
these tumors. In addition, GBM is highly resistant to radiotherapy and
standard chemotherapy. These features could be explained, at least
partially, by the presence within the tumor mass of a small sub-popu-
lation of cells called Glioma Stem-like Cells or Glioma Initiating Cells
(GICs), due to their similarity with the normal stem cells and to their
capacity to initiate and maintain tumor growth [4–6]. Current treat-
ments against GBM include surgical removal of the tumor (which, in
many occasions is partial depending on the proximity of the tumor mass
to eloquent brain regions), focal radiotherapy [1,3] and treatment with
different chemotherapeutic agents, being the most widely used the al-
kylating agent temozolomide (TMZ) [2,3,7]. All these treatments ex-
hibit limited efficacy and thus it is crucial to develop new therapeutic
strategies that help to fight more efficiently this disease. Today is
considered that the development of new therapies based on the com-
bination of various anticancer agents, including those targeting GICs,
together with an increase in the selectivity of the treatments [8,9], may
contribute to enhance the survival of patients with GBM.
Δ9-Tetrahydrocannabinol (THC), the main active ingredient derived
from Cannabis sativa [10], exerts its biological effects by mimicking the
actions of a family of endogenous bioactive lipid mediators named
endocannabinoids. Thus, THC binds and activate two specific G pro-
tein–coupled cannabinoid receptors: CB1 and CB2 [11]. CB1 is highly
expressed in different brain regions although it is also present in many
tissues outside of the central nervous system. CB2 is abundant in the
immune system although it is also present in other tissues and in many
types of cancer cells including glioma cells [11–13]. Nowadays, can-
nabinoids are being investigated as potential therapeutic agents for the
management of different pathologies [14–16], including cancer [17,18]
Thus, treatment with cannabinoid has been shown to inhibit tumor
growth in different animal models of cancer [17–21]. These findings led
to the development of a first pilot clinical study aimed at testing the
anti-cancer activity of THC on recurrent GBM [22]. The mechanism
underlying these anticancer actions of THC has been partially clarified
and relies on the stimulation of an ER stress-related signaling pathway
that triggers the up-regulation of Tribbles pseudokinase 3 and the
subsequent stimulation of autophagy-mediated cancer cell death
[19,23,17,18,20].
Aside from THC, C. sativa produces more than 150 other cannabi-
noids [24] although, unlike THC, many of them exhibit little affinity for
CB receptors [15,25]. Of importance, one of these phytocannabinoids,
namely cannabidiol (CBD), has been shown to exhibit antineoplastic
activity in animal models of cancer including gliomas [25–29]. The
mechanism by which CBD exerts its anti-cancer activity is not com-
pletely understood, although it has been proposed to rely on the ability
to promote the accumulation of reactive oxygen species (ROS) [30], a
mechanism that it is also activated in glioma cells [26,28]. The po-
tential therapeutic interest of the combined administration of THC and
CBD is being investigated for the treatment of different diseases
[15,25,31]. Specifically, THC and CBD have been shown to inhibit the
proliferation and survival of cancer cells in vitro [31] and in animal
models of cancer [32,33]. Moreover, we found that the co-administra-
tion of TMZ with THC and with THC+CBD (at a 1:1 ratio) exerts a
strong anti-tumoral action in glioma xenografts [33,34]. These findings
led to the development of a clinical study where the effect of TMZ
administered in combination with the cannabinoid-based medicine
Sativex (containing THC and CBD in a 1:1 ratio) has been investigated
in patients with recurrent GBM (NCT01812603 and NCT01812616).
One issue that remained to be analyzed is whether CBD alone or
combinations of THC and CBD other than those containing the same
amount of the two cannabinoids may also have anticancer activity
when administered together with other anticancer agents. Results
presented here support the idea that administration of TMZ in combi-
nation with cannabinoid preparations containing a higher proportion of
CBD than of THC (but not CBD alone) target more efficiently the GICs
population.
2. Materials and methods
2.1. Reagents
Pure THC and CBD were obtained from THC Pharm Company
(Frankfurt, Germany). THC botanical drug substance (THC-BDS con-
taining 67.6% THC w/w; 0.3% CBD w/w; other individual plant can-
nabinoids< 1.7% w/w) and CBD-botanical drug substance (CBD-BDS
containing 65.4% CBD w/w; 3.2% THC w/w; other individual plant
cannabinoids< 1.7% w/w) were obtained from GW Pharmaceuticals
(Cambridge, UK). THC-BDS and CBD-BDS were obtained as a resin,
dissolved in ethanol at a concentration of 100mg/mL, and stored at
−20 °C. The required amounts of each component were dried,
weighted, and diluted in dimethyl sulfoxide (DMSO). Treatments con-
taining different THC:CBD ratios were prepared from pure THC and
CBD or from the corresponding Botanical drug substances (BDS) ex-
tracts enriched in each of the two cannabinoids. In this latter case the
total amount of THC and CBD present in the BDS extracts was used to
calculate the amounts to be administered to obtain the appropriate
proportions of each cannabinoid. TMZ was purchased from Merck
(Darmstadt, Germany). Drugs were prepared in DMSO for in vitro ex-
periments. Control incubations contained the same amount of DMSO
and no significant effect was observed in any of the parameters de-
termined throughout this study at the final concentration used
(< 0.5%, v/v).
2.2. Cell cultures
The human brain U87MG (ATCC® HTB-14™) cell line was purchased
from ATCC (Manassas, Virginia, USA) and cultured in Dulbecco's
Modified Eagle Medium (DMEM) containing 10% FBS. Glioblastoma
patient-derived cells with stem-like properties (Glioma Initiating Cells,
GICs) were obtained from human GBM tumor samples from the Spanish
National Cancer Center (CNIO, Madrid, Spain) biobank (GH2-GICs
cells) [35] and from Hospital 12 de Octubre (Madrid, Spain) (12O12-
GICs cells) [36]. All procedures involving samples of human origin were
performed with the approval of the corresponding ethical committees
from each institution as well as of the ethical committee of Complutense
University. Briefly, GICs cultures were obtained by using the following
procedure: tumors samples were mechanic and enzymatically dis-
sociated with Collagenase type Ia from Clostridium histolyticum (Sigma
#C9722, Saint Louis, MS, USA) for 2 h at 37 °C and filtered using a
100 µm nylon filter (Millipore, ref 352360, Burlington, MA, USA). Cells
obtained after this procedure were then plated and maintained as non-
adherent cultures of neuro-spheres for at least 3 consecutive passages in
a DMEM:Ham’s F-12 media supplemented with 1% penicillin–strepto-
micin and HEPES buffer (Lonza, Basel, Switzerland), 0.5% ultra-
glutamine 200 nM (Lonza), 20 ng/ml EGF and FGFb (Gibco, Carlsbad,
USA), 2 µg/ml heparin sodium salt (Sigma), 1% B27 (Invitrogen,
Carlsbad, USA) and 1% leukemia inhibitory factor LIF (Millipore). En-
richment in GICs was analyzed by testing the expression of stem cell
markers in these cultures. All cell cultures were incubated at 37 °C, 5%
CO2. Experiments were performed using U87MG cultures of< 28 pas-
sages and GICs cultures between passages 3 and 15.
2.3. Generation of tumor xenografts
For heterothopic/subcutaneous xenografts, 5× 106 U87MG cells
resuspended in 100 µl of PBS supplemented with 0.1% glucose were
subcutaneously injected in the right flank of 5 week-old (male or fe-
male) nude mice (Harlan Laboratories, Indiana, USA) weighting ap-
proximately 25 g. Tumors were daily measured with an external caliper,
and volume was calculated as (4π/3)× (width/2)2× (length/2). When
tumors had reached an average size of 200mm3, animals were ran-
domly assigned to different groups and treatments with the corre-
sponding drugs commenced. Cannabinoids were diluted in sesame oil
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and orally administered by using an oral gavage. TMZ was diluted in
PBS supplemented with 5mg/ml BSA. Once the treatments were com-
pleted, animals were sacrificed and tumors excised for further analyses.
For the generation of intracranial/orthotopic xenografts, 3× 105
U87 MG cells resuspended in 4 µl of PBS or 7.5× 104 12O12 GICs re-
suspended in 4 µl of supplemented GIC-medium were stereotactically
injected into the right cerebral hemisphere of nude mice at a depth of
3mm. Animals were previously anesthetized with isoflurane and sub-
sequently treated with a mixture of buprenorphine (0.1 mg/kg) and
meloxicam (1mg/kg). Tumor growth was followed by magnetic re-
sonance imaging (MRI) analysis. In the experiments with U87MG-cell
derived orthotopic xenografts, once the tumors were detected, mice
were randomly assigned to different experimental groups and treat-
ments started at the indicated time points. In the experiment with GICs,
treatments started the following day after the injection of the cells. The
monitoring of tumor growth by magnetic resonance imaging was per-
formed at the Nuclear Magnetic Resonance Centre of Complutense
University (Madrid, Spain) using a BIOSPEC BMT 47/40 (Bruker,
Ettlingen, Germany). Tumor volume was calculated using the Image J
software from T1-weighted images. All procedures involving animals
were performed with the approval of the corresponding ethical com-
mittees from Complutense University and Madrid region according to
European regulations.
2.4. Analysis of self-renewal and proliferation capacity of GICs
Nonadherent cultures of GICs were plated at a density of 104 cells/
ml (passage 0, P0) and incubated with the different treatments for
5 days. The spheres formed in each well were then dissociated, counted
(passage 1, P1) and equal number of cells re-plated and incubated again
with the corresponding treatments for 5 additional days. This procedure
was repeated for two consecutive passages (passage 2, P2).
2.5. Limiting dilution assays (LDA)
Nonadherent cultures of GICs were plated at density of 104 cells/ml
and incubated with the different treatments for 5 days. Spheres formed
were dissociated and plated in 96-well plates at different densities (200,
100, 50, 20 and 10 cells per well, respectively). One week later, each
well was scored for tumorsphere formation and wells in which there
was at least one neurosphere were considered positive. Results corre-
spond to the number of wells for each experimental condition in which
neurospheres were found. Results were analyzed using ELDA software
application [37].
2.6. Western blot
Western blot analysis was performed following standard methods.
Briefly, cells were lysed in a buffer containing 50mM Tris-HCl, 0.1%
Triton X-100, 50mM NaF, 10mM sodium glicerophosphate, 5 mM so-
dium pyrophosphate and 1mM sodium orthovanadate, 1 µg/ml leu-
peptin, 1 mM EDTA, EGTA, 200 µM β-mercaptoethanol and 200 µM
microcystin and centrifuged at 12.000 rpm for 15min. Protein con-
centration was determined by Bradford assay. Proteins were electro-
phoretically separated in SDS-polyacrylamide gels (Bio-Rad, Hercules,
CA, USA), transferred onto PVDF membranes (Bio-Rad), blocked in a
5% skim milk solution or 5% BSA (Sigma) and incubated at 4 °C
overnight with a primary antibody: cleaved-PARP Asp 214 [(1:1000);
#9541 Cell Signaling (Danver, MS, USA)] and α-tubulin (1:4000,
Sigma). Immunoreactivity was detected using the enhanced chemilu-
minescence (ECL) system (Bio-Rad). Densitometric quantification was
performed by ImageJ software.
2.7. Statistical analysis
Unless otherwise indicated, data are expressed as mean ± standard
error of the mean (SEM). Analysis of variance (ANOVA) test was per-
formed for multi-component comparisons (one-way or two-way
ANOVA) using the GraphPad Prism 6.0 software. χ2-test was used for
LDA experiments. The survival of nude mice was analyzed by Kaplan-
Meier curves and differences were compared by log-rank test analysis.
P-value of< 0.05 was considered significant.
3. Results
3.1. Effect of THC and CBD mixtures containing a higher proportion of CBD
in combination with TMZ on the growth of U87MG cell-derived xenografts
Previous research by our group has shown that the administration of
THC and of THC and CBD at a 1:1 ratio in combination with temozo-
lomide (TMZ) exerts a strong anticancer activity in glioma xenografts
[33] and (López Valero et al submitted manuscript). Since CBD has also
been found to have anticancer activity in different cancer models in-
cluding gliomas [38–40] we first asked whether the combination of
CBD and TMZ may also produce a synergistic reduction on the growth
of glioma xenografts. In disagreement with this hypothesis, adminis-
tration of CBD and TMZ produced a lower decrease in tumor growth
than the administration of TMZ alone (Fig. 1A), indicating that CBD
does not enhance TMZ anticancer activity and supporting the notion
that the presence of at least a certain amount of THC is required to
observe an enhanced anticancer activity of TMZ.
Therefore, next we investigated the anticancer activity of combi-
nations of THC and CBD containing a higher proportion of CBD on the
growth of glioma xenografts. As shown in Fig. 1B, the administration of
BDS extracts containing THC and CBD at a 1:4 ratio produced a similar
reduction on the growth of U87MG cell-derived subcutaneous xeno-
grafts (and enhanced the effect of TMZ at a similar extent) than the
administration of THC and CBD at a 1:1 ratio. To further characterize
the effect of THC-CBD combinations on this model, we next investigated
whether this enhanced effect of the combination of THC and CBD with
TMZ was preserved using lower doses of THC. In line with this hy-
pothesis, administration of BDS extracts containing THC and CBD at a
1:4 and 1:6 ratio produced a similar reduction on the growth of tumor
xenografts (and enhanced the effect of TMZ at a similar extent) than the
administration of THC:CBD at a 1:1 ratio (Fig. 1C).
To investigate the potential relevance of these findings in a model
that resembles more closely the treatments that take place in patients
with GBM, next, we analyzed the effect of BDS extracts containing THC
and CBD at a 1:4 ratio in combination with TMZ in orthotopic xeno-
grafts generated by intracranial injection of U87MG cells (Fig. 2A). The
combined administration of THC and CBD at a 1:4 ratio together with
TMZ significantly enhanced the effect of this alkylating agent on the
growth of the tumors (as determined by MRI) (Fig. 2B) as well as in the
survival of the animals (Fig. 2C). Taken together, these observations
support the notion that combinations of THC and CBD containing a
higher proportion of CBD produce a similar anticancer effect on glioma
xenografts (and enhance the anticancer activity of TMZ at a similar
extent) than the administration of THC and CBD at a 1:1 ratio.
3.2. Effect of THC and CBD mixtures containing a higher proportion of CBD
in combination with TMZ on the population of Glioma Initiating Cells
The population of cancer stem-like cells derived from glioma or
Glioma Initiating Cells (GICs) is a small cell subpopulation present in
GBM tumors that has features of stem cells and that has been proposed
to be responsible for the relapses occurring in most patients with this
disease [41]. Therefore, finding new therapeutic approaches capable of
targeting this cell subpopulation have great interest to enhance the
efficacy of current therapies against GBM [41]. One of the character-
istics of GICs is that they are highly resistant to most anticancer
therapies [41]. In addition, GICs exhibit a relatively slow proliferation
rate and can self-renew undergoing asymmetric divisions [41]. We
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therefore asked whether different ratios of THC and CBD in combina-
tion with TMZ may target the population of GICs. As a first approach to
test this hypothesis we analyzed the effect of the different treatments on
the proliferation during two consecutive passages of primary cultures of
GICs derived from human GBM samples grown as non-adherent
spheroid cultures. As shown in Fig. 3A, treatment with THC and CBD at
a 1:5 ratio produced a stronger reduction (and enhanced at a further
extent the effect of TMZ) on the proliferation of GH2-GICs than THC
and CBD at a 1:1 ratio or than TMZ alone. Similar results were obtained
with 12O12 cells where the strongest effect was consistently observed
upon exposure to THC:CBD 1:5+TMZ (Fig. 3B). In any case, differ-
ences between THC:CBD 1:5+TMZ and the rest of the treatments were
non-significant. Next, we analyzed the effect of these drug combina-
tions on the ability to generate “neurospheres” of primary cultures of
GICs (an estimation of the self-renewal capacity of these cells) by per-
forming the limiting dilution assay (LDA). As shown in Fig. 3C and D
treatment with THC and CBD at a 1:5 ratio inhibited the formation of
neurospheres at a higher extent than TMZ or than the combination of
THC and CBD at a 1:1 ratio. Likewise, the combination of TMZ with
THC and CBD at a 1:5 ratio produced a stronger inhibition on neuro-
sphere formation than the treatment with THC and CBD at a 1:1 ratio in
combination with TMZ, and almost completely inhibited the formation
of neurospheres. Moreover, treatment with THC:CBD at a 1:5 ratio in-
duced apoptosis of GICs (as determined by the cleavage of the caspase 3
Fig. 1. THC and CBD combinations con-
taining a higher proportion of CBD inhibit
the growth of subcutaneous U87 MG cell-
derived-glioma xenografts and enhance the
anticancer activity of TMZ to a similar ex-
tent than THC and CBD at a 1:1 ratio. (A)
Left panel: Effect of daily oral administra-
tion of CBD (15mg/kg) and TMZ (5mg/kg,
I.P. administration) on the growth of
U87MG cell–derived subcutaneous xeno-
grafts (mean ± SEM, n=6–8 animals for
each condition). Symbols of significance are
omitted for clarity. CBD-treated tumors
were significantly different from vehicle-
treated tumors from day 5 to day 13
(P < 0.05), and from day 14 until the end
of the treatment (P < 0.01); TMZ-treated
tumors were significantly different from
vehicle-treated tumors at day 4 (P < 0.05)
and from day 5 until the end of the treat-
ment (P < 0.01); CBD+TMZ-treated tu-
mors were significantly different from ve-
hicle-treated tumors from day 5 to day 12
(P < 0.05), and from day 13 until the end
of the treatment (P < 0.01). Right panel:
Data correspond to the change in tumor
volume in the last day of the treatment and
are expressed as the mean fold-change in
tumor volume ± SEM relative to the first
day of the treatment. **P < 0.01 from ve-
hicle-treated tumors. (B) Effect of daily oral
administration of THC:CBD (1:1 ratio) [THC
(5mg/kg)+CBD (5mg/kg)], THC:CBD
(1:4 ratio) [THC (6.5mg/kg)+CBD
(24.5 mg/kg)] and TMZ (5mg/kg, I.P. ad-
ministration) on the growth of U87MG
cell–derived subcutaneous xenografts
(mean ± SEM, n= 6–7 animals for each
condition). The total mg of THC and CBD
administered in each case were obtained by
mixing the corresponding amounts of THC:BDS and CBD:BDS extracts. Symbols of significance are omitted for clarity. THC:CBD (1:1 ratio)-treated tumors were
significantly different from vehicle-treated tumors from day 12 until the end of the treatment (P < 0.001). THC:CBD (1:4 ratio)-treated tumors were significantly
different from vehicle-treated tumors at days 10,11 (P < 0.05) and from day 12 until the end of the treatment (P < 0.001); TMZ-treated tumors were significantly
different from vehicle-treated tumors from day 8 to day 11 (P < 0.01) and from day 12 until the end of the treatment (P < 0.001); THC:CBD (1:1 ratio) +TMZ-
treated tumors were significantly different from vehicle-treated tumors from day 5 until the end of the treatment (P < 0.001); significantly different from THC:CBD
(1:1)-treated tumors from day 7 to day 9 (P < 0.01) and from day 10 until the end of the treatment (P < 0.001); and significantly different from TMZ-treated
tumors at days 14 (P < 0.05), 15 (P < 0.01) and from day 16 until the end of the treatment (P < 0.001). THC:CBD (1:4 ratio)+TMZ-treated tumors were
significantly different from vehicle-treated tumors from day 5 until the end of the treatment (P < 0.001); significantly different from THC:CBD (1:4)-treated tumors
from day 7 to day10 (P < 0.01) and from day 11 until the end of the treatment (P < 0.001); and significantly different from TMZ-treated tumors from day 13 to day
15 (P < 0.01); and from day 16 until the end of the treatment (P < 0.001). (C) Effect of daily oral administration of THC:CBD (1:1 ratio) [THC (3.5mg/kg)+CBD
(3.5 mg/kg)], THC:CBD (1:4 ratio) [THC (4.5 mg/kg)+CBD (16.5 mg/kg), THC:CBD (1:6 ratio) [THC (5.2mg/kg)+CBD (29.5mg/kg) and TMZ (5mg/kg, I.P.
administration) on the growth of U87MG cell–derived subcutaneous xenografts (mean ± SEM, n= 6–7 animals for each condition). The total mg of THC and CBD
administered in each case were obtained by mixing the corresponding amounts of THC:BDS and CBD:BDS extracts.. Symbols of significance are omitted for clarity. At
day 14 (the last day of treatments), all the treatments were significantly different from vehicle (P < 0.001). THC:CBD (1:1 ratio)+TMZ-treated tumors were
significantly different from individually-treated tumors (P < 0.001); THC:CBD (1:4 ratio)+TMZ and THC:CBD (1:6 ratio)+TMZ treated tumors were significantly
different from individually-treated tumors (P < 0.01). THC:CBD (1:4 ratio)-treated tumors were significantly different from THC:CBD (1:6 ratio)-treated tumor
(P < 0.05).
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substrate PARP) at higher extent than treatment with TMZ or with
THC:CBD at a 1:1 ratio alone (Fig. 3E and F). Similarly, the combined
administration of TMZ and THC:CBD at a 1:5 ratio activated apoptosis
at a higher extent than TMZ+THC:CBD at a 1:1 ratio (Fig. 3E and F).
To test the in vivo relevance of these observations we analyzed the
effect of the different treatments on orthotopic xenografts generated by
intracranial injection of 12O12 GICs in immunodeficient mice (Fig. 4A).
As shown in Fig. 4B, oral administration of THC and CBD at a 1:1 or 1:5
ratio alone did not significantly affect tumor size (as determined by
MRI). However treatment with THC:CBD at a 1:5 ratio alone but not
with THC:CBD at a 1:1 ratio increased the survival of the animals
(Fig. 4C). More importantly, the combined administration of TMZ and
THC:CBD at a 1:1 and 1:5 ratios reduced tumor growth and had a more
potent effect on the survival of the animals than treatment with TMZ
Fig. 2. The administration of THC:CBD (1:4 ratio) and TMZ strongly reduce tumor growth and enhances the survival of mice bearing U87MG cell-derived intracranial
xenografts. (A) Scheme of the experimental design. (B) Effect of the oral administration of THC:CBD (1:4 ratio) [THC (6.5 mg/kg)+CBD (24.5 mg/kg)] and TMZ
(5mg/kg, I.P. administration) on the size of glioma xenografts (as determined by MRI) generated by intracranial injection of 3 x 105 U87MG cells (n=6–7). The total
mg of THC and CBD administered in each case were obtained by mixing the corresponding amounts of THC:BDS and CBD:BDS extracts. Left panel: Representative
MRI images at different time points for each experimental condition are shown. Right panel: Data correspond to the increase in tumor volume at day 21 and are
expressed as the mean fold change in tumor volume relative to day 7 ± SEM; (n= 5–7) *P < 0.05 or **P < 0.01 from vehicle-treated tumors. (C) Effect of the
different treatments on the survival of mice bearing orthotopic tumor xenografts generated by intracranial injection of 3 x 105 U87MG cells. Data correspond to the
percentage of alive animals along the experiment for each treatment and are depicted in Kaplan-Meier plot (n=8–10) ***P < 0.001 from vehicle-treated tumors. &&
&P < 0.001 from THC:CBD (1:4 ratio)-treated tumors; #P < 0.05 from TMZ-treated tumors.
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alone. Furthermore, the combined administration of THC and CBD at a
1:5 ratio and TMZ reduced tumor growth and increased animal survival
at a higher extent than treatment with THC:CBD at a 1:1 ratio in
combination with TMZ. Altogether, these observations support the idea
that the combined administration of TMZ with THC:CBD preparations
has anticancer activity in GICs in vitro and in vivo. In addition, our
findings also support that cannabinoid combinations containing a
higher proportion of CBD target the population of GICs more efficiently
than THC:CBD at a 1:1 ratio.
4. Discussion
Previous findings by our group and others have shown that THC as
well as CBD have anticancer activity in animal models of glioma
[17,18,40,42,43]. Moreover, it was also found that the combination of
THC and CBD at a 1:1 ratio produces a similar effect as THC and that
the combination of TMZ [the benchmark agent for the treatment of
GBM] and THC [or THC and CBD (at a 1:1 ratio)], strongly enhances the
tumor inhibitory activity of the administration of THC, TMZ or
THC+CBD at a 1:1 ratio alone [33].
Of note, cannabinoid preparations containing CBD only or different
amounts of THC and CBD are currently being explored for different
therapeutic applications [25] and therefore it could be relevant from
the clinical point of view to know whether CBD alone or combinations
of THC and CBD other than those containing the same amount of the
two cannabinoids may also have anticancer activity when administered
together with other antineoplastic agents. Results presented here in-
dicate that, the combined administration of TMZ and CBD does not
enhance the tumor-inhibitory activity of TMZ in glioma xenografts and
that therefore cannabinoid-based combinational antitumoral therapies
Fig. 3. THC:CBD (1:5 ratio) inhibits GICs
proliferation and self-renewal of GICs to a
higher extent than THC-CBD (1:1 ratio). (A-
B) Effect of the treatment with THC:CBD
(1:1 ratio) [2.5 µM THC+2.5 µM CBD];
THC:CBD (1:5 ratio) [0.83 µM
THC+4.17 µM CBD] and TMZ (100 µM,
panel A or 20 µM, panel B) during 2 con-
secutive passages on the proliferation and
self-renewal capacity of GH2-GICs (panel A)
and 12O12-GICs (panel B) grown as spher-
oids. Data correspond to the total number of
cells counted upon disaggregation of
spheroid cultures in each passage and are
expressed as the mean fold-change from the
number of cells plated at P0 ± SEM. n= 3.
*P < 0.05, **P < 0.01 or *** P < 0.001
from vehicle-treated cells; ### P < 0.001
from TMZ-treated cells. Treatment of GH2-
GICs with THC:CBD (1:1 ratio)+TMZ or
THC:CBD (1:5 ratio)+ TMZ were sig-
nificantly different (P < 0.05) from treat-
ment with THC:CBD (1:1 ratio) and
THC:CBD (1:5 ratio). Treatment with
THC:CBD (1:5)+ TMZ was significantly
different (P < 0.05) from THC:CBD
(1:1)+ TMZ. (C-D) Effect of THC:CBD (1:1
ratio) [2.5 µM THC+2.5 µM CBD];
THC:CBD (1:5 ratio) [0.83 µM
THC+4.17 µM CBD] and TMZ (100 µM,
panel C or 20 µM, panel D) on the self-re-
newal ability (as determined by limiting
dilution assays) of GH2-GICs (panel C) and
12O12-GICs (panel D). A representative ex-
periment of 2 (Panels C and D) is shown.
Data corresponds to the fraction of cells
with ability to generate new spheres cul-
tures. Graphs were obtained using the ELDA
software application that fits the data ob-
tained for each experimental condition to
the limiting dilution model. The slope of the
depicted solid lines corresponds to the
fraction of cells with ability to generate new
spheres cultures. Decreased slopes indicate
a lower fraction of cells with capacity to
generate new spheres. The dotted lines in-
dicate the 95% confidence interval.
**P < 0.01 or ***P < 0.001 from vehicle-
treated cells; ##P < 0.01 or ###P < 0.001
from TMZ-treated cells; $$$P < 0.001 from
THC:CBD (1:1 ratio); &&&P < 0.001 from THC:CBD (1:5 ratio); and ¥P < 0.05 from THC:CBD (1:1)+ TMZ. (E) Effect of THC:CBD (1:1 ratio) [3.5 µM THC+3.5 µM
CBD]; THC:CBD (1:5 ratio) [1.16 µM THC+5.83 µM CBD] and TMZ (100 µM) on apoptosis (as determined by the cleavage of the CASPASE 3 substrate PARP) of
GH2-GICs (48 h). Left panel: A representative western blot experiment is shown (n= 3). Right panel: Densitometric analysis of cleaved PARP levels. Data are
expressed as mean fold change in cleaved PARP levels relative to tubulin levels in each experimental condition ± SEM. *P < 0,05 from vehicle-treated cells.
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containing CBD may require the presence of THC (even if at sub-
maximal concentrations) to produce an enhanced anticancer effect
when administered in combination with TMZ. In support of this idea,
the administration of extracts containing a higher proportion of CBD
than of THC enhanced TMZ anticancer activity at the same extent than
THC:CBD at a 1:1 ratio. These observations suggest that therapies based
on the use of cannabinoid-based medicines containing a higher pro-
portion of CBD than of THC (and that therefore are expected to have a
Fig. 4. The combination of THC:CBD (1:5 ratio)+TMZ reduces tumor growth and increases animal survival of mice bearing 12O12 GICs-derived intracranial
xenografts to a higher extent than combination of THC:CBD (1:1 ratio)+TMZ. (A) Scheme of the in vivo experiment. (B) Effect of oral administration of THC:CBD
(1:1 ratio) [THC (5mg/kg)+CBD (5mg/kg)], THC:CBD (1:5 ratio) [THC (5mg/kg)+CBD (25mg/kg)] and TMZ (5mg/kg, I.P. administration) on the size of
glioma xenografts (as determined by MRI) generated by intracranial injection of 7.5× 104 12O12 GICs (n= 6–7). Left panel: Representative MRI images of each
experimental condition after 4 weeks of treatment are shown. Right panel: Data correspond to the volume of the tumors at day 28 after the injection of the cells and
the commencement of the treatments and are expressed as mean ± SEM; (n=5–7) **P < 0.01 or ***P < 0.001 from vehicle-treated tumors; $$$P < 0.001 from
THC:CBD (1:1 ratio)-treated tumors and &&P < 0.01 from THC:CBD (1:5)-treated tumors. (C) Effect of the different treatments on the survival of mice bearing 12O12
GICs derived intracranial xenografts. Data correspond to the percentage of alive animals along the experiment for each treatment and are depicted in Kaplan-Meier
plot (n=8–10). Symbols of significance are omitted for clarity. Survival of THC:CBD (1:5 ratio)-treated animals was significantly different (P < 0.01) from vehicle-
treated animals; Survival of TMZ, THC:CBD (1:1)+TMZ- and THC:CBD (1:5 ratio)+ TMZ-treated animals was significantly different (P < 0.001) from vehicle-
treated animals. Survival of THC:CBD (1:1 ratio)+TMZ-treated animals was significantly different (P < 0.001) from THC:CBD (1:1 ratio)-treated animals. Survival
of THC:CBD (1:5 ratio)+TMZ-treated animals was significantly different (P < 0.01) from TMZ-treated animals and from THC:CBD (1:5 ratio)-treated animals
(P < 0.001). Survival of THC:CBD (1:5 ratio)+TMZ-treated animals was significantly different (P < 0.05) from THC:CBD (1:1 ratio)+ TMZ-treated animals.
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lower psychoactive profile than those containing a higher proportion of
THC [44,45]) in combination with chemotherapeutic agents (and spe-
cifically with TMZ), may also be of potential interest for the design of
novel therapeutic strategies to treat gliomas.
The aggressiveness of GBM is, at least in part, due to the presence
within the tumor mass of a small cell population of GICs that exhibits a
high resistance to therapy and that has been proposed to be responsible
for the relapses that take place in most if not all the patients suffering
this devastating disease [46]. Since targeting this cell population might
be particularly relevant in the context of novel anti-GBM therapies, in
this work we also investigated the effect of THC:CBD combinations
administered together with TMZ on GICs derived from human GBM
tumors. Of note, previous work showed that synthetic agonists of can-
nabinoid receptors can promote the differentiation of GICs [35]. Like-
wise, CBD has been shown to inhibit the self-renewal of GICs and in-
crease the survival of animals bearing intracranial xenografts derived
from these cells [38,40]. Findings presented here now show that
treatment with the combination of THC, CBD and TMZ leads to the
activation of apoptosis, and in turn to a very significant reduction (or
even to a complete elimination) of this cell population in vitro. In ad-
dition, and in contrast with the results obtained with differentiated
glioma cells (Figs. 1 and 2), our in vitro and in vivo observations support
the idea that the treatments with THC:CBD combinations containing a
higher proportion of CBD targets more efficiently the population of
GICs than THC:CBD at a 1:1 ratio.
Preclinical work performed during the past couple of decades has
contributed to set the bases for the development of the first clinical
studies to analyze the potential anticancer activity of cannabinoid-
based medicines. Specifically, a clinical trial to investigate the effect of
the combination of the cannabinoid-based medicine Sativex® and TMZ
on recurrent GBM has been recently completed (NCT01812616) and it
is expected that additional studies will follow in the near future. Results
presented in this manuscript now support the notion that cannabinoid
combinations containing a higher amount of CBD than of THC in
combination with TMZ target more efficiently the GICs population
(maintaining the same anticancer efficacy on differentiated glioma
cells) than THC:CBD 1:1 combinations. These findings suggest that the
utilization of cannabinoid-based medicines containing a higher amount
of CBD than of THC in combination with TMZ may have an advantage
over preparations containing the same amount of THC and CBD in the
treatment of GBM. Whether this therapeutic approach could be bene-
ficial at least for a fraction of GBM patients is an interesting possibility
that might deserve to be therapeutically explored in future clinical
studies.
Acknowledgements
This work has been funded by the PI15/00339 grant, integrated into
the State Plan for R & D+ I2013-2016 and funded by the Instituto de
Salud Carlos III (ISCIII) (Spain) and the European Regional
Development Fund (ERDF) and by grants from Spanish Ministry of
Economy and Competitiveness (MINECO)/ISCIII and ERDF (PS09/
01401; PI12/02248,to GV), GW Pharma Ltd. (UK), Comunidad de
Madrid (Spain) (S2011/BMD-2308 to MG), Fundación Mutua
Madrileña (Spain) (AP101042012 to GV), Fundació La Marató de TV3
(Spain) (201334031 to GV), Voices Against Brain Cancer (US), and
donations by The Medical Cannabis Bike Tour Foundation (The
Netherlands) and Jeff Ditchfield. Israel López-Valero was supported by
a predoctoral P-FIS contract from Instituto de Salud Carlos III (ISCIII)
and Cristina Sáiz was supported by a “Juan de la Cierva formación”
contract of the Spanish Ministry of Economy and Competitiveness.
Conflict of interest
Part of the work included in this manuscript was funded by GW
Pharma ltd.
References
[1] D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella-Branger,
W.K. Cavenee, H. Ohgaki, O.D. Wiestler, P. Kleihues, D.W. Ellison, The 2016 World
Health Organization classification of tumors of the central nervous system: a
summary, Acta Neuropathol. 131 (6) (2016) 803–820.
[2] C. Nieder, M. Adam, M. Molls, A.L. Grosu, Therapeutic options for recurrent high-
grade glioma in adult patients: recent advances, Crit. Rev. Oncol. Hematol. 60 (3)
(2006) 181–193.
[3] M.L. Wong, A.H. Kaye, C.M. Hovens, Targeting malignant glioma survival signalling
to improve clinical outcomes, J. Clin. Neurosci. 14 (4) (2007) 301–308.
[4] R.K. Balvers, C.M. Dirven, S. Leenstra, M.L. Lamfers, Malignant glioma in vitro
models: on the utilization of stem-like cells, Curr. Cancer Drug Targets 17 (3)
(2016) 255–266.
[5] J. Chen, Y. Li, T.S. Yu, R.M. McKay, D.K. Burns, S.G. Kernie, L.F. Parada, A re-
stricted cell population propagates glioblastoma growth after chemotherapy,
Nature 488 (7412) (2012) 522–526.
[6] B.D. Liebelt, T. Shingu, X. Zhou, J. Ren, S.A. Shin, J. Hu, Glioma stem cells: sig-
naling, microenvironment, and therapy, Stem Cells Int. (2016) 7849890.
[7] R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn,
K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer,
S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer,
R.O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma, N. Engl. J. Med. 352 (10) (2005) 987–996.
[8] C.W. Brennan, R.G. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S.R. Salama,
S. Zheng, D. Chakravarty, J.Z. Sanborn, S.H. Berman, R. Beroukhim, B. Bernard,
C.J. Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna,
S.A. Shukla, G. Ciriello, W.K. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, K. Aldape,
D.D. Bigner, E.G. Van Meir, M. Prados, A. Sloan, K.L. Black, J. Eschbacher,
G. Finocchiaro, W. Friedman, D.W. Andrews, A. Guha, M. Iacocca, B.P. O'Neill,
G. Foltz, J. Myers, D.J. Weisenberger, R. Penny, R. Kucherlapati, C.M. Perou,
D.N. Hayes, R. Gibbs, M. Marra, G.B. Mills, E. Lander, P. Spellman, R. Wilson,
C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P.W. Laird, D. Haussler, G. Getz,
L. Chin, The somatic genomic landscape of glioblastoma, Cell 155 (2) (2013)
462–477.
[9] R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, M.D. Wilkerson,
C.R. Miller, L. Ding, T. Golub, J.P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly,
P. Tamayo, B.A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H.S. Feiler,
J.G. Hodgson, C.D. James, J.N. Sarkaria, C. Brennan, A. Kahn, P.T. Spellman,
R.K. Wilson, T.P. Speed, J.W. Gray, M. Meyerson, G. Getz, C.M. Perou, D.N. Hayes,
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell 17
(1) (2010) 98–110.
[10] Y. Gaoni, R. Mechoulam, Isolation, structure and partial synthesis of an active
constituent of hashish, J. Am. Chem. Soc. 86 (1964) 1646–1647.
[11] A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder,
M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, R.G. Pertwee, International
union of pharmacology. XXVII. Classification of cannabinoid receptors, Pharmacol.
Rev. 54 (2) (2002) 161–202.
[12] J. Fernandez-Ruiz, J. Romero, G. Velasco, R.M. Tolon, J.A. Ramos, M. Guzman,
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends
Pharmacol. Sci. 28 (1) (2007) 39–45.
[13] R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick,
P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, R.A. Ross,
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid re-
ceptors and their ligands: beyond CB(1) and CB(2, Pharmacol. Rev. 62 (4) (2010)
588–631.
[14] V. Di Marzo, The endocannabinoid system: its general strategy of action, tools for its
pharmacological manipulation and potential therapeutic exploitation, Pharmacol.
Res. 60 (2) (2009) 77–84.
[15] R.G. Pertwee, Emerging strategies for exploiting cannabinoid receptor agonists as
medicines, Br. J. Pharmacol. 156 (3) (2009) 397–411.
[16] R.G. Pertwee, Endocannabinoids and Their Pharmacological Actions, Handb. Exp.
Pharmacol. 231 (2015) 1–37.
[17] G. Velasco, S. Hernandez-Tiedra, D. Davila, M. Lorente, The use of cannabinoids as
anticancer agents, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2015)
259–266.
[18] G. Velasco, C. Sanchez, M. Guzman, Towards the use of cannabinoids as antitumour
agents, Nat. Rev. Cancer 12 (6) (2012) 436–444.
[19] A. Carracedo, M. Lorente, A. Egia, C. Blazquez, S. Garcia, V. Giroux, C. Malicet,
R. Villuendas, M. Gironella, L. Gonzalez-Feria, M.A. Piris, J.L. Iovanna, M. Guzman,
G. Velasco, The stress-regulated protein p8 mediates cannabinoid-induced apoptosis
of tumor cells, Cancer Cell 9 (4) (2006) 301–312.
[20] S. Hernandez-Tiedra, G. Fabrias, D. Davila, I.J. Salanueva, J. Casas, L.R. Montes,
Z. Anton, E. Garcia-Taboada, M. Salazar-Roa, M. Lorente, J. Nylandsted,
J. Armstrong, I. Lopez-Valero, C.S. McKee, A. Serrano-Puebla, R. Garcia-Lopez,
J. Gonzalez-Martinez, J.L. Abad, K. Hanada, P. Boya, F. Goni, M. Guzman, P. Lovat,
M. Jaattela, A. Alonso, G. Velasco, Dihydroceramide accumulation mediates cyto-
toxic autophagy of cancer cells via autolysosome destabilization, Autophagy 12
(11) (2016) 2213–2229.
[21] M. Salazar, A. Carracedo, I.J. Salanueva, S. Hernandez-Tiedra, M. Lorente, A. Egia,
P. Vazquez, C. Blazquez, S. Torres, S. Garcia, J. Nowak, G.M. Fimia, M. Piacentini,
F. Cecconi, P.P. Pandolfi, L. Gonzalez-Feria, J.L. Iovanna, M. Guzman, P. Boya,
G. Velasco, Cannabinoid action induces autophagy-mediated cell death through
stimulation of ER stress in human glioma cells, J. Clin. Invest. 119 (5) (2009)
I. López-Valero et al. Biochemical Pharmacology 157 (2018) 266–274
273
1359–1372.
[22] M. Guzman, M.J. Duarte, C. Blazquez, J. Ravina, M.C. Rosa, I. Galve-Roperh,
C. Sanchez, G. Velasco, L. Gonzalez-Feria, A pilot clinical study of Delta9-tetra-
hydrocannabinol in patients with recurrent glioblastoma multiforme, Br. J. Cancer
95 (2) (2006) 197–203.
[23] A. Carracedo, M. Gironella, M. Lorente, S. Garcia, M. Guzman, G. Velasco,
J.L. Iovanna, Cannabinoids induce apoptosis of pancreatic tumor cells via en-
doplasmic reticulum stress-related genes, Cancer Res. 66 (13) (2006) 6748–6755.
[24] L.O. Hanus, S.M. Meyer, E. Munoz, O. Taglialatela-Scafati, G. Appendino,
Phytocannabinoids: a unified critical inventory, Nat. Prod. Rep. 33 (12) (2016)
1357–1392.
[25] A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, R. Mechoulam, Non-psychotropic
plant cannabinoids: new therapeutic opportunities from an ancient herb, Trends
Pharmacol. Sci. 30 (10) (2009) 515–527.
[26] P. Massi, A. Vaccani, S. Bianchessi, B. Costa, P. Macchi, D. Parolaro, The non-psy-
choactive cannabidiol triggers caspase activation and oxidative stress in human
glioma cells, Cell. Mol. Life Sci. 63 (17) (2006) 2057–2066.
[27] P. Massi, A. Vaccani, S. Ceruti, A. Colombo, M.P. Abbracchio, D. Parolaro,
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma
cell lines, J. Pharmacol. Exp. Ther. 308 (3) (2004) 838–845.
[28] P. Massi, M. Valenti, A. Vaccani, V. Gasperi, G. Perletti, E. Marras, F. Fezza,
M. Maccarrone, D. Parolaro, 5-Lipoxygenase and anandamide hydrolase (FAAH)
mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid, J.
Neurochem. 104 (4) (2008) 1091–1100.
[29] S.D. McAllister, R.T. Christian, M.P. Horowitz, A. Garcia, P.Y. Desprez, Cannabidiol
as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, Mol.
Cancer Ther. 6 (11) (2007) 2921–2927.
[30] A. Ligresti, A.S. Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis,
C. Laezza, G. Portella, M. Bifulco, V. Di Marzo, Antitumor activity of plant canna-
binoids with emphasis on the effect of cannabidiol on human breast carcinoma, J.
Pharmacol. Exp. Ther. 318 (3) (2006) 1375–1387.
[31] J.P. Marcu, R.T. Christian, D. Lau, A.J. Zielinski, M.P. Horowitz, J. Lee, A. Pakdel,
J. Allison, C. Limbad, D.H. Moore, G.L. Yount, P.Y. Desprez, S.D. McAllister,
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on
human glioblastoma cell proliferation and survival, Mol. Cancer Ther. 9 (1) (2010)
180–189.
[32] K.A. Scott, A.G. Dalgleish, W.M. Liu, The combination of cannabidiol and Delta9-
tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic
murine glioma model, Mol. Cancer Ther. 13 (12) (2014) 2955–2967.
[33] S. Torres, M. Lorente, F. Rodriguez-Fornes, S. Hernandez-Tiedra, M. Salazar,
E. Garcia-Taboada, J. Barcia, M. Guzman, G. Velasco, A combined preclinical
therapy of cannabinoids and temozolomide against glioma, Mol. Cancer Ther. 10
(1) (2011) 90–103.
[34] I. Lopez-Valero, S. Torres, M. Salazar-Roa, E. Garcia-Taboada, S. Hernandez Tiedra,
M. Guzman, J.M. Sepulveda, G. Velasco, M. Lorente, Optimization of a preclinical
therapy of cannabinoids in combination with temozolomide against glioma,
Biochem. Pharmacol. (2018), https://doi.org/10.1016/j.bcp.2018.08.023 (Epub
ahead of print).
[35] T. Aguado, A. Carracedo, B. Julien, G. Velasco, G. Milman, R. Mechoulam,
L. Alvarez, M. Guzman, I. Galve-Roperh, Cannabinoids induce glioma stem-like cell
differentiation and inhibit gliomagenesis, J. Biol. Chem. 282 (9) (2007) 6854–6862.
[36] N. Pozo, C. Zahonero, P. Fernandez, J.M. Linares, A. Ayuso, M. Hagiwara, A. Perez,
J.R. Ricoy, A. Hernandez-Lain, J.M. Sepulveda, P. Sanchez-Gomez, Inhibition of
DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth, J.
Clin. Invest. 123 (6) (2013) 2475–2487.
[37] Y. Hu, G.K. Smyth, ELDA: extreme limiting dilution analysis for comparing depleted
and enriched populations in stem cell and other assays, J. Immunol. Methods 347
(1–2) (2009) 70–78.
[38] E. Singer, J. Judkins, N. Salomonis, L. Matlaf, P. Soteropoulos, S. McAllister,
L. Soroceanu, Reactive oxygen species-mediated therapeutic response and re-
sistance in glioblastoma, Cell Death Dis. 6 (2015) e1601.
[39] M. Solinas, P. Massi, V. Cinquina, M. Valenti, D. Bolognini, M. Gariboldi, E. Monti,
T. Rubino, D. Parolaro, Cannabidiol, a non-psychoactive cannabinoid compound,
inhibits proliferation and invasion in U87-MG and T98G glioma cells through a
multitarget effect, PLoS One 8 (10) (2013) e76918.
[40] L. Soroceanu, R. Murase, C. Limbad, E. Singer, J. Allison, I. Adrados, R. Kawamura,
A. Pakdel, Y. Fukuyo, D. Nguyen, S. Khan, R. Arauz, G.L. Yount, D.H. Moore,
P.Y. Desprez, S.D. McAllister, Id-1 is a key transcriptional regulator of glioblastoma
aggressiveness and a novel therapeutic target, Cancer Res. 73 (5) (2012)
1559–1569.
[41] D.A. Spencer, B.M. Auffinger, J.P. Murphy, M.E. Muroski, J. Qiao, Y. Gorind,
M.S. Lesniak, Hitting a moving target: glioma stem cells demand new approaches in
glioblastoma therapy, Curr. Cancer Drug Targets 17 (3) (2016) 236–254.
[42] P. Massi, M. Solinas, V. Cinquina, D. Parolaro, Cannabidiol as potential anticancer
drug, Br. J. Clin. Pharmacol. 75 (2) (2013) 303–312.
[43] A. Vaccani, P. Massi, A. Colombo, T. Rubino, D. Parolaro, Cannabidiol inhibits
human glioma cell migration through a cannabinoid receptor-independent me-
chanism, Br. J. Pharmacol. 144 (8) (2005) 1032–1036.
[44] R.J. Niesink, S. Rigter, M.W. Koeter, T.M. Brunt, Potency trends of Delta9-tetra-
hydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands:
2005-15, Addiction 110 (12) (2015) 1941–1950.
[45] R.J. Niesink, M.W. van Laar, Does cannabidiol protect against adverse psycholo-
gical effects of THC? Front. Psychiatry 4 (2013) 130.
[46] S. Osuka, E.G. Van Meir, Overcoming therapeutic resistance in glioblastoma: the
way forward, J. Clin. Invest. 127 (2) (2017) 415–426.
I. López-Valero et al. Biochemical Pharmacology 157 (2018) 266–274
274
